Skip to main content
. 2008 Jul 14;19(8):774–782. doi: 10.1089/hum.2008.036

FIG. 1.

FIG. 1.

GLV-1h68 infects, replicates in, and has varying and dose-dependent cytotoxicity in a panel of malignant mesothelioma cell lines in vitro. (A) Overlay image showing no GFP expression in MSTO-211H cells immediately after infection with GLV-1h68. (B) Abundant GFP expression in MSTO-211H cells 24 hr after infection with virus. On close examination, all the infected cells have lost their normal morphology and have detached from the bottom of the plate, and some of them seem to be undergoing oncolysis. (C) The percentage cell survival of all the human (epithelioid, mixed, and sarcomatoid) and murine mesothelioma cell lines tested at an MOI of 1.0 demonstrates the cytotoxic effect of GLV-1h68 over time. Oncolytic vaccinia virus killed 100% of MSTO-211H and H-2052 cells by days 4 and 7, respectively. (D) LDH cytotoxicity assay on MSTO-211H cells performed daily after viral treatment shows effective oncolytic activity of GLV-1h68 at all doses tested (MOIs of 1.0, 0.1, and 0.01); activity occurred in a dose-dependent manner with 100% cell killing by days 4, 5, and 7, respectively. (E) Viral proliferation assay of GLV-1h68-treated MSTO-211H cells shows a 4-log increase in plaque-forming units of GLV-1h68 by day 7, demonstrating that the oncolytic vaccinia virus is able to replicate within the mesothelioma cells in vitro.